Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus ...

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have increased their exposure ...

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

A high dose of centanafadine was shown to be safe and effective at lowering ADHD symptoms for adolescents, according to ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the quarter’s ...

Some women’s symptoms improved quickly after taking the pill, but depression persisted in others. Doctors are trying to learn which patients benefit, and why some don’t.

The botulinum toxin market is projected to grow at a CAGR of approximately 10% from 2025 to 2030. This growth is driven by ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...